Biotinylated Human IL-5 Protein
Catalog No: IL5-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human IL-5 Protein is expressed in HEK293 cells with a His tag and Avi tag at the N-terminus. It contains amino acid residues Ile20-Ser134 (UniProt accession: P05113).
Product Details
- Molecular Aliases
- Interleukin-5; IL-5; T-cell replacing factor; TRF; EDF;IL5;IL 5; Interleukin 5
- Protein Length
- Ile20-Ser134
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 16.1 kDa. Due to glycosylation, the protein migrates to 18-25 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 24 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human IL-5 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human IL-5 is greater than 95% as determined by SEC-HPLC.
Immobilized Human IL-5 R alpha, hFc Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Human IL-5, His Tag with the EC50 of 68.2ng/ml determined by ELISA (QC Test).
Human IL-5 R alpha, His Tag immobilized on CM5 Chip can bind Biotinylated Human IL-5, His-Avi tag with an affinity constant of 7.57 nM as determined in SPR assay (Biacore T200).
Background
IL-5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. IL-5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophilic syndrome (HES), eosinophilic esophagitis (EE), and eosinophilic granulomatosis with polyangiitis (EGPA).
References
- Hassani M, Koenderman L. Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview. Allergy. 2018 Oct;73(10):1979-1988. doi: 10.1111/all.13451. Epub 2018 Oct 8. PMID: 29611207; PMCID: PMC6220846.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.